Oncology 61, 129133. For more detailed information on the cookies we use, please check our Privacy Policy. (2005). Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad. Webcasts and presentations from ESMO 2017 can be accessed by ESMO members and event attendees. Int. Koshiba et al. A framework to rank genomic alterations as targets for cancer precision medicine.ESCAT scores for genomic alterations with actionable drug matches are now being gradually integrated into ESMO tumour-focused Clinical Practice Guidelines. Our results revealed carboplatin-related hypersensitivity reactions in 1 out of 10 women treated with a carboplatin-containing regimen for ovarian, fallopian tube, or primary peritoneal cancer. These differences were likely related to the fact that patients with advanced disease, serous carcinoma, and ascetic malignant cells required significantly more carboplatin treatment cycles and higher carboplatin doses. Accessibility It would be worthwhile to evaluate the correlation between other HRD genes and carboplatin hypersensitivity. Gynecol. Multivariate analyses of clinical parameters for carboplatin-related hypersensitivity reactions. Copyright 2017 Tai, Tai, Hsu, Lee, Chen, Chiang, Chen, Chen and Cheng. Nitipir C, Parosanu A, Popa AM, Cotan H, Olaru M, Iaciu C, Orlov Slavu C. Cureus. Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches. Merck KGaA, Darmstadt, Germany: Driving Innovation in Cancer Care at Incidence and Management of Olaratumab Infusion-Related Reactions. Risk Factors of Hypersensitivity to Carboplatin in Patients with Overall, the evidence supports that the number of carboplatin cycles and dose are the principal risk factors for carboplatin-related hypersensitivity reactions, and that caution is warranted in cases of carboplatin infusion beyond 8 cycles or 3,500 mg. Utilizing Biologics in Drug Desensitization. del Carmen Sancho M, Breslow R, Sloane D, Castells M. Chem Immunol Allergy. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. also successfully developed a platinum desensitization protocol for patients with either a positive carboplatin skin test or a history of prior carboplatin hypersensitivity (Altwerger et al., 2017). 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. Carboplatin and other paltins such as cisplatin and oxaliplatin reactions include classical symptoms of anaphylaxis with cutaneous, respiratory, cardiovascular, and gastrointestinal symptoms. The experience from Women and Infants' Hospital. doi: 10.1093/annonc/mdy158. 2023 Feb 15;24(4):3886. doi: 10.3390/ijms24043886. Oncol. Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Tumori 89, 311313. It didn't disappoint. Libra, M., Sorio, R., Buonadonna, A., Berretta, M., Stefanovski, P., Toffoli, G., et al. Statistical analyses were performed using the Statistical Package of Social Studies (SPSS) version 17.0 (SPSS, Inc., Chicago, IL) and SAS software version 9.4 (SAS Inc, NC, USA) for Windows. The ESMO Clinical Practice Guidelines (CPGs) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. Most events occurred during chemotherapy. Invest. (2017). We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. The cumulative incidence of carboplatin-related hypersensitivity was 2% after 8 cycles, 6% after 14 cycles, 8% after 19 cycles, and 10% after 33 cycles, with a plateau beyond this cycle number (Figure 1A). In addition, the development of a new generation of platinum cytotoxic drugs to avoid hypersensitivity reactions is warranted. doi: 10.1016/j.ygyno.2006.10.047, Shah, A. C., Minturn, J. E., Li, Y., Belasco, J. ESMO Colloquia are innovative sessions within the Congress programme, organised by ESMO and supported by industry, Information about the exhibition and Satellite Symposia, Contact details and welcome message, plus other general information about ESMO 2017. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., et al. (2006). The https:// ensures that you are connecting to the Table 6. There was a striking difference in PFSmedian 16.8 versus 5.6 months, HR 0.52 (highly significant)with the difference in PFS sustained at 12- and 18-month landmarks. A total of 59 women experienced mild signs and symptoms (grades 1 and 2), including skin rash (69.3%), skin itching (64.0%), facial flushing (56.0%), dyspnea (41.3%), chest pain (25.3%), tachycardia (18.7%), paresthesias (16.0%), abdominal cramping (13.3%), and diaphoresis (12.0%). Markman et al. J. Gynecol. Disclaimer. Abstracts, slide sets and webcasts from ESMO 2017 Congress are now available. Abe, A., Ikawa, H., and Ikawa, S. (2010). (2003). van de Loosdrecht, Arjan A. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. -. Table 1. Adnan A, Acharya S, Alenazy LA, de Las Vecillas L, Giavina Bianchi P, Picard M, Calbache-Gil L, Romero-Pinedo S, Abad A-Molina AC, Kerr W, Pedicone C, Nagai J, Hollers E, Dwyer D, Castells M. J Immunol. See this image and copyright information in PMC. Supportive and Palliative Care | ESMO 66, 265267. Atopic patients are at increased risk for chemotherapy and MoAbs drug allergy and the current patterns of treatment with recurrent and intermittent drug exposures may favor the development of drug allergies. ESMO is a Swiss-registered not-for-profit organisation. 2022 Oct 18;12:994155. doi: 10.3389/fonc.2022.994155. (2013). Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. 107, 163165. Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies. doi: 10.1200/JCO.2006.06.0913, Polyzos, A., Tsavaris, N., Kosmas, C., Arnaouti, T., Kalahanis, N., Tsigris, C., et al. 2018 Jun;54(3):375-385. doi: 10.1007/s12016-016-8556-5. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. We also found higher rates of hypersensitivity among patients with malignant ascites compared to patients without malignant ascites (P = 0.009, chi-squared test), and in patients who had experienced allergic reactions to other medications or food (e.g., paclitaxel, penicillin, aspirin) compared to patients who had not experienced previous allergic reactions (P < 0.001, chi-squared test). Our findings also suggest that a history of drug or food allergies is a predictive factor for carboplatin-related hypersensitivity. Chemother. 10.1016/annonc/annonc687, Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC), Targeted Therapies and Precision Oncology, Interpreting Oncological Study Publications, Cancer Diagnosis and Treatment Evaluation, Cancer Treatment in Special Clinical Situations, Clinical Pharmacology of Anti-Cancer Agents, Controversies in upper GI oncology: ESMO Open Podcasts, International Prognostic Index Tools for Lymphoma, Anti-Cancer Agents and Biological Therapy, Drug-Drug Interactions with Kinase Inhibitors, PARP inhibition and DNA Damage Response (DDR), Cancer Aetiology, Epidemiology and Prevention, Cancer in Special situations (pregnancy, young, elderly, hereditary), Multikinase Inhibitor-Related Skin Toxicity, Precision Medicine and Validated Biomarkers, ESMO Recommendations in Precision Medicine. doi: 10.1007/s10147-014-0731-1. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Successful carboplatin desensitization in patients with proven carboplatin allergy. Expert Opin Drug Saf (2003) 2(6):597607.10.1517/14740338.2.6.597 Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. (2012) demonstrated that carboplatin treatment can be continued successfully in patients whose hypersensitivity reactions are managed in a timely fashion. Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P. Classical and new chemotherapy drugs, monoclonal antibodies (MoAbs), and small molecules to treat cancer and chronic inflammatory diseases are aimed at improving quality of life and life expectancy of patients, but an increasing number of reactions including anaphylaxis precludes their use in targeted populations. Cancer 109, 10721078. The rate of hypersensitivity to carboplatin did not differ by patient age, menopausal status, disease entity, receipt of optimal debulking, or the amount of ascites. Patients should be observed closely for hypersensitivity reactions for a minimum of 30 minutes following each IV iron . Supportive. Cancer 63, 2126. hypersensitivity and pneumonitis not otherwise specified. Management of infusion reactions to systemic anticancer therapy: ESMO (2011) found that the number of treatment cycles with platinum-containing antineoplastic agents significantly correlates with the incidence of related hypersensitivity reactions. ESMO is a Swiss-registered not-for-profit organisation. doi: 10.1002/pbc.25697, Siegel, R. L., Miller, K. D., and Jemal, A. Clin Rev Allergy Immunol. J. Clin. Analysis included treatment cycle, causative drug, severity of reaction as per CTCAE v4 . Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. doi: 10.1111/j.1525-1438.2007.01063.x, Genc, D. B., Canpolat, C., and Berrak, S. G. (2012). This was the largest series of gynecological malignancies investigated for carboplatin-related hypersensitivity reactions. The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B ). Such reactions were scored according to the Common Terminology Criteria for Adverse Events version 4.03, with severity assessed as mild (grades 1 and 2) or severe (grades 3 and 4). Anticancer.
Steve Mariucci Salary,
Morgantown, Wv Indictments 2020,
Enchanted Forest Cabins Central Coast,
Middle Name For Callahan,
Bone Spicule After Wisdom Tooth Extraction,
Articles E